vs
Side-by-side financial comparison of AMN HEALTHCARE SERVICES INC (AMN) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
AMN HEALTHCARE SERVICES INC is the larger business by last-quarter revenue ($748.2M vs $622.0M, roughly 1.2× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs -1.0%, a 35.5% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs 1.8%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -4.5%).
AMN Healthcare Services Inc. is a leading US healthcare sector workforce solutions and staffing provider. It offers temporary and permanent placement for nurses, physicians, allied health and other clinical/non-clinical staff, plus workforce management tools and consulting for hospitals, clinics and other medical facilities.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
AMN vs RPRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $748.2M | $622.0M |
| Net Profit | $-7.7M | $214.2M |
| Gross Margin | 26.1% | — |
| Operating Margin | 1.1% | 62.4% |
| Net Margin | -1.0% | 34.4% |
| Revenue YoY | 1.8% | 4.8% |
| Net Profit YoY | 95.9% | 2.9% |
| EPS (diluted) | $-0.19 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $748.2M | $622.0M | ||
| Q3 25 | $634.5M | $609.3M | ||
| Q2 25 | $658.2M | $578.7M | ||
| Q1 25 | $689.5M | $568.2M | ||
| Q4 24 | $734.7M | $593.6M | ||
| Q3 24 | $687.5M | $564.7M | ||
| Q2 24 | $740.7M | $537.3M | ||
| Q1 24 | $820.9M | $568.0M |
| Q4 25 | $-7.7M | $214.2M | ||
| Q3 25 | $29.3M | $288.2M | ||
| Q2 25 | $-116.2M | $30.2M | ||
| Q1 25 | $-1.1M | $238.3M | ||
| Q4 24 | $-187.5M | $208.2M | ||
| Q3 24 | $7.0M | $544.0M | ||
| Q2 24 | $16.2M | $102.0M | ||
| Q1 24 | $17.3M | $4.8M |
| Q4 25 | 26.1% | — | ||
| Q3 25 | 29.1% | — | ||
| Q2 25 | 29.8% | — | ||
| Q1 25 | 28.7% | — | ||
| Q4 24 | 29.8% | — | ||
| Q3 24 | 31.0% | — | ||
| Q2 24 | 31.0% | — | ||
| Q1 24 | 31.4% | — |
| Q4 25 | 1.1% | 62.4% | ||
| Q3 25 | 7.5% | 70.1% | ||
| Q2 25 | -18.8% | 36.3% | ||
| Q1 25 | 1.8% | 94.0% | ||
| Q4 24 | -27.6% | 60.9% | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 5.1% | 50.2% | ||
| Q1 24 | 4.9% | -13.0% |
| Q4 25 | -1.0% | 34.4% | ||
| Q3 25 | 4.6% | 47.3% | ||
| Q2 25 | -17.7% | 5.2% | ||
| Q1 25 | -0.2% | 41.9% | ||
| Q4 24 | -25.5% | 35.1% | ||
| Q3 24 | 1.0% | 96.3% | ||
| Q2 24 | 2.2% | 19.0% | ||
| Q1 24 | 2.1% | 0.8% |
| Q4 25 | $-0.19 | $0.49 | ||
| Q3 25 | $0.76 | $0.67 | ||
| Q2 25 | $-3.02 | $0.07 | ||
| Q1 25 | $-0.03 | $0.55 | ||
| Q4 24 | $-4.90 | $0.46 | ||
| Q3 24 | $0.18 | $1.21 | ||
| Q2 24 | $0.42 | $0.23 | ||
| Q1 24 | $0.45 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $34.0M | $618.7M |
| Total DebtLower is stronger | $767.1M | $9.0B |
| Stockholders' EquityBook value | $642.1M | $9.7B |
| Total Assets | $2.1B | $19.6B |
| Debt / EquityLower = less leverage | 1.19× | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $34.0M | $618.7M | ||
| Q3 25 | $52.6M | $938.9M | ||
| Q2 25 | $41.5M | $631.9M | ||
| Q1 25 | $55.8M | $1.1B | ||
| Q4 24 | $10.6M | $929.0M | ||
| Q3 24 | $30.6M | $950.1M | ||
| Q2 24 | $48.0M | $1.8B | ||
| Q1 24 | $50.6M | $843.0M |
| Q4 25 | $767.1M | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $1.1B | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
| Q4 25 | $642.1M | $9.7B | ||
| Q3 25 | $644.4M | $9.6B | ||
| Q2 25 | $607.6M | $9.5B | ||
| Q1 25 | $715.1M | $9.8B | ||
| Q4 24 | $706.6M | $10.3B | ||
| Q3 24 | $890.7M | $10.3B | ||
| Q2 24 | $876.9M | $9.8B | ||
| Q1 24 | $854.2M | $9.9B |
| Q4 25 | $2.1B | $19.6B | ||
| Q3 25 | $2.1B | $19.3B | ||
| Q2 25 | $2.2B | $18.3B | ||
| Q1 25 | $2.4B | $17.6B | ||
| Q4 24 | $2.4B | $18.2B | ||
| Q3 24 | $2.7B | $18.0B | ||
| Q2 24 | $2.8B | $17.7B | ||
| Q1 24 | $2.9B | $16.1B |
| Q4 25 | 1.19× | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | 1.49× | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $75.6M | $827.1M |
| Free Cash FlowOCF − Capex | $67.6M | — |
| FCF MarginFCF / Revenue | 9.0% | — |
| Capex IntensityCapex / Revenue | 1.1% | — |
| Cash ConversionOCF / Net Profit | — | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | $233.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $75.6M | $827.1M | ||
| Q3 25 | $22.7M | $702.6M | ||
| Q2 25 | $78.5M | $364.0M | ||
| Q1 25 | $92.7M | $596.1M | ||
| Q4 24 | $72.8M | $742.5M | ||
| Q3 24 | $66.7M | $703.6M | ||
| Q2 24 | $99.5M | $658.2M | ||
| Q1 24 | $81.4M | $664.6M |
| Q4 25 | $67.6M | — | ||
| Q3 25 | $14.8M | — | ||
| Q2 25 | $68.7M | — | ||
| Q1 25 | $82.7M | — | ||
| Q4 24 | $56.6M | — | ||
| Q3 24 | $47.4M | — | ||
| Q2 24 | $72.2M | — | ||
| Q1 24 | $63.2M | — |
| Q4 25 | 9.0% | — | ||
| Q3 25 | 2.3% | — | ||
| Q2 25 | 10.4% | — | ||
| Q1 25 | 12.0% | — | ||
| Q4 24 | 7.7% | — | ||
| Q3 24 | 6.9% | — | ||
| Q2 24 | 9.8% | — | ||
| Q1 24 | 7.7% | — |
| Q4 25 | 1.1% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 1.4% | — | ||
| Q4 24 | 2.2% | — | ||
| Q3 24 | 2.8% | — | ||
| Q2 24 | 3.7% | — | ||
| Q1 24 | 2.2% | — |
| Q4 25 | — | 3.86× | ||
| Q3 25 | 0.77× | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | 9.54× | 1.29× | ||
| Q2 24 | 6.13× | 6.45× | ||
| Q1 24 | 4.70× | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMN
| Travel Nurse Staffing | $208.3M | 28% |
| Allied Staffing | $146.9M | 20% |
| Labor Disruption Services | $124.3M | 17% |
| Technology And Workforce Solutions | $88.0M | 12% |
| Language Services | $69.9M | 9% |
| Other | $29.6M | 4% |
| International Nurse Staffing | $29.6M | 4% |
| Interim Leadership Staffing | $24.1M | 3% |
| Vendor Management Systems | $16.3M | 2% |
| Local Staffing | $8.6M | 1% |
| International Nurse Permanent Placement | $2.6M | 0% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
